• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Neptune Wellness Solutions Inc.

    2/15/24 5:16:35 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEPT alert in real time by email
    NT 10-Q 1 nept20240215_nt10q.htm FORM NT 10-Q nept20240215_nt10q.htm

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SEC FILE NUMBER:001-33526

    CUSIP NUMBER: 64079L303

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN

     

    ☐ Form N-CSR

     

     

     

    For Period Ended: December 31, 2023

     

    ☐ Transition Report on Form 10-K

     

    ☐ Transition Report on Form 20-F

     

    ☐ Transition Report on Form 11-K

     

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended: _____________

     

     

    Read Instructions (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    ____________________________________________________________________________________

     

    PART I - REGISTRANT INFORMATION

     

    NEPTUNE WELLNESS SOLUTIONS INC.

     

    _____________________________________________________________________________________

    Full Name of Registrant

     

    _____________________________________________________________________________________

    Former Name if Applicable

     

    100-545 Promenade du Centropolis

    _____________________________________________________________________________________

    Address of Principal Executive Office (Street and Number)

     

    Laval, Quebec, Canada H7T 0A3

    _____________________________________________________________________________________

    City, State and Zip Code

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     
     

    (a)

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)

    The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

     

     

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    (Attach extra sheets if Needed)

     

    See Attachment A.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     

     

     

     

     

     

     

    Lisa Gainsborg

     

    450

     

    687-2262

     

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

     

     

     

     

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    Yes ☐ No ☒

     

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    Yes ☒ No ☐  

     

     

     

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    Total revenues are expected to be approximately  $7.6 million versus $12.2 million in the corresponding period for last fiscal year. We expect to report cost of goods sold of approximately $6.6 million versus $10.3 million in the corresponding period for the last fiscal year. Gross profit is expected to be approximately $1.0 million versus $1.9 million in the corresponding period for the last fiscal year. Selling, general and administrative expenses are expected to be approximately $18.7 million versus $8.7 million in the corresponding period for the last fiscal year. We expect to report loss from operating activities of approximately $17.7 million versus $7.1 million in the corresponding period for the last fiscal year.

     

     

     

     

     

     

     

     

     

     

     

     

    NEPTUNE WELLNESS SOLUTIONS INC.

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 15, 2024

    By:

    /s/ Lisa Gainsborg

     

    Name:

    Lisa Gainsborg

     

    Title:

    Interim Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

    ATTACHMENT A

    EXPLANATORY NOTE:

    This Form 12b-25: Notification of Late Filing (this “Form 12b-25”) is being filed by Neptune Wellness Solutions Inc. (the “Company”) to seek an extension of the filing deadline for its Quarterly Report on Form 10-Q for the three months ended December 31, 2023 (“Quarterly Report”) pursuant to Rule 12b-25 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

    The due date for the filing of the Quarterly Report is February 14, 2023 (the “Filing Deadline”). Pursuant to the filing of this Form 12b-25, the due date for the filing of the Quarterly Report is being extended to February 20, 2024 (“Extended Filing Deadline”). The Company expects to file its Form 10-Q for the three months ended December 31, 2023 on or before the Extended Filing Deadline.

     

    Part III – Narrative

    The Company hereby confirms that it is unable to file the Quarterly Report by the Filing Deadline without unreasonable effort or expense. The Company has limited accounting and financial personnel and therefore requires additional time to compile and process the information necessary for the completion of the Form 10-Q. The Company has reported and will continue to report ineffective disclosure controls and procedures and internal controls over financial reporting as of December 31, 2023 in the Company’s Form 10-Q to be filed.

     

           

     

     

     
    Get the next $NEPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Neptune Securities Settlement Fund sold $13,601 worth of shares (200,300 units at $0.07), decreasing direct ownership by 25% to 1,048,334 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    4/30/24 12:01:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $35,224 worth of shares (81,814 units at $0.43), decreasing direct ownership by 7% to 1,671,302 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    3/6/24 11:04:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $187,949 worth of shares (247,604 units at $0.76), decreasing direct ownership by 12% to 1,778,380 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    11/30/23 5:26:53 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    SEC Filings

    View All

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    5/6/24 2:26:26 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Neptune Wellness Solutions Inc.

    25-NSE - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    4/25/24 9:09:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    4/12/24 5:02:21 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Financials

    Live finance-specific insights

    View All

    Neptune Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

    Consolidated revenues for fiscal 2023 totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022 Q4 net sales $12.1 million, up 5% from last year's $11.5 million Sprout maintained a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally1 Sprout was available in 90% of footprint the Organic Baby Food market across all 50 U.S. states and Canada Company to host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023 LAVAL, QC, July 17, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustai

    7/17/23 5:38:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune to Report Fiscal Third Quarter 2023 Financial Results on March 30, 2023

    Company to host a conference call at 5:00 p.m. (Eastern Time) LAVAL, QC, March 30, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the third quarter of fiscal 2023 after the market close on Thursday, March 30, 2023. The Company will host a conference call at 5:00 p.m. (Eastern Time) today, Thursday, March 30, 2023, to discuss these results. The conference call wil

    3/30/23 11:28:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Receipt of NASDAQ Notification

    LAVAL, QC, Feb. 24, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) ), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that the Company has received written notification from the Listing Qualification Department of the Nasdaq Stock Market LLC on February 23, 2023, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), as a result of Neptune not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission.  

    2/24/23 4:05:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Leadership Updates

    Live Leadership Updates

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Reports Fiscal Third Quarter 2024 Financial Results

    LAVAL, QC / ACCESSWIRE / February 16, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for its fiscal third quarter 2024 ending December 31, 2023.Recent Business HighlightsAnnounced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related

    2/16/24 5:35:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

    LAVAL, QC / ACCESSWIRE / January 24, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related to Sprout Organics.Stifel brings a wealth of experience and expertise in the financial sector, having successfully facilitated nume

    1/24/24 9:00:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    2/12/24 6:48:47 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    1/2/24 2:02:04 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Neptune Wellness Solutions Inc.

    SC 13D - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    10/17/23 11:57:17 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Decision of Nasdaq Hearings Panel To Delist Common Shares

    LAVAL, QC / ACCESSWIRE / March 6, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced an update on the status of its appeal against the determination of the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to delist the Company's common shares ("Common Shares").As previously disclosed, the Company had been notified by Nasdaq on November 30, 2023 that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below US$1.00 for 30 consecutive trading days and that it was not in comp

    3/6/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Michael Cammarata's Resignation Effective February 23, 2024

    LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced that Michael Cammarata has resigned from his role as President and Chief Executive Officer effective February 23, 2024. We thank Michael for his service and wish him best of luck in his future endeavors.About Neptune Wellness Solutions Inc.Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest marke

    3/4/24 8:31:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care